Berlin Cures GmbH is a clinical stage pharmaceutical company developing a short DNA aptamer BC 007 for the treatment of pathogenic autoantibodies against G-protein coupled receptors.
A dose-escalating study evaluated the safety, tolerability, pharmacokinetics and mode of action of BC 007 after a single intravenous infusion. The publication is entitled: "A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects".
BC 007 plasma and urine concentrations were estimated by Accelero Bioanalytic GmbH on the basis of a validated enzyme-linked sandwich hybridisation assay.
The results have been published by Becker NP et al in Clinical Drug Investigation May 2020, 40(5), pages 433-447, doi: 10.1007/s40261-020-00903-9. PubMed ID: 32222912.